Corvus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Corvus Pharmaceuticals (CRVS).

Price Target Range — 9 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$29Upside to Avg. PT+176.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 17, 2026	Goldman Sachs	Paul Choi	Initiate	Buy	$40
Mar 13, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$32→$33
Jan 22, 2026	Jefferies	Roger Song	PT Raise	Buy	$13→$42
Jan 21, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$15→$32
Jan 21, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$16→$28
Jan 20, 2026	HC Wainwright & Co.	Sean Lee	PT Raise	Buy	$11→$27
Oct 13, 2025	Barclays	Etzer Darout	Initiate	Overweight	$16
May 20, 2025	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$12→$11
May 9, 2025	Oppenheimer	Jeff Jones	PT Raise	Outperform	$15→$17
Mar 26, 2025	Oppenheimer	Jeff Jones	PT Raise	Outperform	$14→$15
Mar 26, 2025	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$11
Jan 14, 2025	HC Wainwright & Co.	Sean Lee	Maintained	Buy	$11
Jan 2, 2025	HC Wainwright & Co.	Sean Lee	Initiate	Buy	$11
Nov 13, 2024	Oppenheimer	Jeff Jones	PT Raise	Outperform	$8→$14
Oct 22, 2024	Mizuho	Graig Suvannavejh	Upgrade	Neutral→Outperform	$4→$12
Sep 16, 2024	Ladenburg Thalmann	Aydin Huseynov	PT Raise	Buy	$12→$21
May 7, 2024	Oppenheimer	Jeff Jones	PT Raise	Outperform	$7→$8
Apr 1, 2024	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
Mar 27, 2024	Mizuho	Graig Suvannavejh	Maintained	Neutral	$4
Mar 20, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$8→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

https://www.cnbc.com/2026/04/17/this-stock-could-more-than-double-on-oral-eczema-treatment-goldman-sachs-says.html

Benzinga Newsdesk

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Avi Kapoor

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

Goldman Sachs analyst Paul Choi initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $40.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

Jefferies analyst Roger Song maintains Corvus Pharma (NASDAQ:CRVS) with a Buy and raises the price target from $13 to $42.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $15 to $32.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

Barclays analyst Etzer Darout maintains Corvus Pharma (NASDAQ:CRVS) with a Overweight and raises the price target from $16 to $28.

Benzinga Newsdesk

Corvus Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Corvus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

People Also Watch

People Also Watch

Corvus Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Corvus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWatching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

This Woodward Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PROGoldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PROJefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PROOppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PROBarclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28

People Also Watch

People Also Watch

PRO
Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"

PRO
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

PRO
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

PRO
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28